Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 40

1.

Incidence, mortality, and survival trends of soft tissue and bone sarcoma in Switzerland between 1996 and 2015.

Kollár A, Rothermundt C, Klenke F, Bode B, Baumhoer D, Arndt V, Feller A; NICER Working Group.

Cancer Epidemiol. 2019 Sep 11;63:101596. doi: 10.1016/j.canep.2019.101596. [Epub ahead of print]

PMID:
31520938
2.

Analysis of AR/ARV7 Expression in Isolated Circulating Tumor Cells of Patients with Metastatic Castration-Resistant Prostate Cancer (SAKK 08/14 IMPROVE Trial).

Hench IB, Cathomas R, Costa L, Fischer N, Gillessen S, Hench J, Hermanns T, Kremer E, Mingrone W, Mestre RP, Püschel H, Rothermundt C, Ruiz C, Tolnay M, Burg PV, Bubendorf L, Vlajnic T, Sakk SGFCCR.

Cancers (Basel). 2019 Aug 1;11(8). pii: E1099. doi: 10.3390/cancers11081099.

3.

Shared Decision-Making for Patients with Advanced Urological Malignancies: Evaluation of a Joint Urological-Oncological Clinic Model.

Betschart P, Babst C, Schmid S, Rothermundt C, Abt D, Schwab C, Gillessen S, Engeler DS, Klingbiel D, Schmid HP, Omlin A.

Oncol Res Treat. 2019;42(7-8):366-374. doi: 10.1159/000499721. Epub 2019 Jun 6.

PMID:
31170721
4.

Impact of Addition of Metformin to Abiraterone in Metastatic Castration-Resistant Prostate Cancer Patients With Disease Progressing While Receiving Abiraterone Treatment (MetAb-Pro): Phase 2 Pilot Study.

Mark M, Klingbiel D, Mey U, Winterhalder R, Rothermundt C, Gillessen S, von Moos R, Pollak M, Manetsch G, Strebel R, Cathomas R.

Clin Genitourin Cancer. 2019 Apr;17(2):e323-e328. doi: 10.1016/j.clgc.2018.12.009. Epub 2019 Jan 2.

PMID:
30686756
5.

Correction to: Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).

Rothermundt C, Thurneisen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, Wehrhahn T, Ruf C, Rothschild SI, Seifert B, Terbuch A, Grassmugg T, Woelky R, Fankhauser C, Kunit T, Fischer N, Inauen R, Kamradt J, Ziegler K, Haynes A, Jüni P, Gillessen S.

Swiss Med Wkly. 2018 Aug 29;148:w14674. doi: 10.4414/smw.2018.14674. eCollection 2018 Aug 27. No abstract available.

6.

Baseline characteristics and patterns of care in testicular cancer patients: first data from the Swiss Austrian German Testicular Cancer Cohort Study (SAG TCCS).

Rothermundt C, Thurneysen C, Cathomas R, Müller B, Mingrone W, Hirschi-Blickenstorfer A, Wehrhahn T, Ruf C, Rothschild S, Seifert B, Terbuch A, Grassmugg T, Woelky R, Fankhauser C, Kunit T, Fischer N, Inauen R, Kamradt J, Ziegler K, Haynes A, Jüni P, Gillessen S.

Swiss Med Wkly. 2018 Jul 24;148:w14640. doi: 10.4414/smw.2018.14640. eCollection 2018. Erratum in: Swiss Med Wkly. 2018 Aug 29;148:w14674. Erratum.

7.

Impact of mammography screening programmes on breast cancer mortality in Switzerland, a country with different regional screening policies.

Herrmann C, Vounatsou P, Thürlimann B, Probst-Hensch N, Rothermundt C, Ess S.

BMJ Open. 2018 Mar 14;8(3):e017806. doi: 10.1136/bmjopen-2017-017806.

8.

Pattern of Care Study in Metastatic Renal-Cell Carcinoma in the Preimmunotherapy Era in Switzerland.

Sandmeier N, Rothschild SI, Rothermundt C, Cathomas R, Schardt J, Berthold D, von Burg P, Müller B, Beyer J, Vogt DR, Stenner F.

Clin Genitourin Cancer. 2018 Aug;16(4):e711-e718. doi: 10.1016/j.clgc.2018.01.002. Epub 2018 Feb 2.

PMID:
29503245
9.

Pre- and Postoperative Chemotherapy in Localized Extremity Soft Tissue Sarcoma: A European Organization for Research and Treatment of Cancer Expert Survey.

Rothermundt C, Fischer GF, Bauer S, Blay JY, Grünwald V, Italiano A, Kasper B, Kollár A, Lindner LH, Miah A, Sleijfer S, Stacchiotti S, Putora PM.

Oncologist. 2018 Apr;23(4):461-467. doi: 10.1634/theoncologist.2017-0391. Epub 2017 Nov 30. Review.

10.

Der etwas andere Husten.

Tschallener M, Knechtle B, Bode-Lesniewska B, Braschler T, Frei E, Rothermundt C, Messerli M.

Praxis (Bern 1994). 2017 Sep;106(19):1065-1070. doi: 10.1024/1661-8157/a002778. German. No abstract available.

PMID:
28927367
11.

Gemcitabine and docetaxel versus doxorubicin as first-line treatment in previously untreated advanced unresectable or metastatic soft-tissue sarcomas (GeDDiS): a randomised controlled phase 3 trial.

Seddon B, Strauss SJ, Whelan J, Leahy M, Woll PJ, Cowie F, Rothermundt C, Wood Z, Benson C, Ali N, Marples M, Veal GJ, Jamieson D, Küver K, Tirabosco R, Forsyth S, Nash S, Dehbi HM, Beare S.

Lancet Oncol. 2017 Oct;18(10):1397-1410. doi: 10.1016/S1470-2045(17)30622-8. Epub 2017 Sep 4.

12.

Applied Swarm-based medicine: collecting decision trees for patterns of algorithms analysis.

Panje CM, Glatzer M, von Rappard J, Rothermundt C, Hundsberger T, Zumstein V, Plasswilm L, Putora PM.

BMC Med Res Methodol. 2017 Aug 16;17(1):123. doi: 10.1186/s12874-017-0400-y.

13.

Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11).

Cathomas R, Crabb SJ, Mark M, Winterhalder R, Rothermundt C, Elliott T, von Burg P, Kenner H, Hayoz S, Vilei SB, Rauch D, Roggero E, Mohaupt MG, Bernhard J, Manetsch G, Gillessen S; Swiss Group for Clinical Cancer Research SAKK.

Prostate. 2016 Dec;76(16):1519-1527. doi: 10.1002/pros.23236. Epub 2016 Jul 25.

PMID:
27457964
14.

Adjuvant Sunitinib in High-Risk Renal-Cell Carcinoma after Nephrectomy.

Ravaud A, Motzer RJ, Pandha HS, George DJ, Pantuck AJ, Patel A, Chang YH, Escudier B, Donskov F, Magheli A, Carteni G, Laguerre B, Tomczak P, Breza J, Gerletti P, Lechuga M, Lin X, Martini JF, Ramaswamy K, Casey M, Staehler M, Patard JJ; S-TRAC Investigators.

N Engl J Med. 2016 Dec 8;375(23):2246-2254. Epub 2016 Oct 9.

15.

Enzalutamide in Patients With Castration-Resistant Prostate Cancer Progressing After Docetaxel: Retrospective Analysis of the Swiss Enzalutamide Named Patient Program.

Papazoglou D, Wannesson L, Berthold D, Cathomas R, Gillessen S, Rothermundt C, Hasler L, Winterhalder R, Barth A, Mingrone W, Nussbaum CU, von Rohr L, von Burg P, Schmid M, Richner J, Baumann S, Kühne R, Stenner F, Rothschild SI.

Clin Genitourin Cancer. 2017 Jun;15(3):e315-e323. doi: 10.1016/j.clgc.2016.06.011. Epub 2016 Jun 23.

PMID:
27450512
16.

Follow-up practices for high-grade extremity Osteosarcoma.

Rothermundt C, Seddon BM, Dileo P, Strauss SJ, Coleman J, Briggs TW, Haile SR, Whelan JS.

BMC Cancer. 2016 May 6;16:301. doi: 10.1186/s12885-016-2333-y.

17.

Rituximab, bendamustine and lenalidomide in patients with aggressive B-cell lymphoma not eligible for anthracycline-based therapy or intensive salvage chemotherapy - SAKK 38/08.

Hitz F, Zucca E, Pabst T, Fischer N, Cairoli A, Samaras P, Caspar CB, Mach N, Krasniqi F, Schmidt A, Rothermundt C, Enoiu M, Eckhardt K, Berardi Vilei S, Rondeau S, Mey U.

Br J Haematol. 2016 Jul;174(2):255-63. doi: 10.1111/bjh.14049. Epub 2016 Mar 28.

PMID:
27018242
18.

Sequence of treatment in locally advanced and metastatic renal cell carcinoma.

Fischer S, Gillessen S, Rothermundt C.

Transl Androl Urol. 2015 Jun;4(3):310-25. doi: 10.3978/j.issn.2223-4683.2015.04.07. Review.

19.

Algorithms in the First-Line Treatment of Metastatic Clear Cell Renal Cell Carcinoma--Analysis Using Diagnostic Nodes.

Rothermundt C, Bailey A, Cerbone L, Eisen T, Escudier B, Gillessen S, Grünwald V, Larkin J, McDermott D, Oldenburg J, Porta C, Rini B, Schmidinger M, Sternberg C, Putora PM.

Oncologist. 2015 Sep;20(9):1028-35. doi: 10.1634/theoncologist.2015-0145. Epub 2015 Aug 3.

20.

Restless Legs Syndrome—An Emerging Potential Side Effect of Enzalutamide: Report of 2 Cases.

Desax MC, Hundsberger T, Rothermundt C, Omlin A, Gillessen S.

Clin Genitourin Cancer. 2015 Oct;13(5):e385-6. doi: 10.1016/j.clgc.2015.04.007. Epub 2015 May 1. No abstract available.

PMID:
26048855

Supplemental Content

Loading ...
Support Center